Developing a Gabapentin Pharmacokinetic Model Using Patient Data
Author Information
Author(s): Firas Al-Zubaydi, Andrew Wassef, Leonid Kagan, Luigi Brunetti, Katarina Vučićević, Branislava Miljković
Primary Institution: Rutgers, The State University of New Jersey
Hypothesis
Can therapeutic drug monitoring concentrations be used to develop a population pharmacokinetic model for gabapentin?
Conclusion
The study found that renal function significantly impacts gabapentin pharmacokinetics, while diabetes and body weight parameters do not.
Supporting Evidence
- The population pharmacokinetic model was developed using real-life clinical data.
- Serum creatinine was identified as a significant covariate affecting clearance.
- Diabetes and body weight parameters did not significantly impact gabapentin pharmacokinetics.
- The model demonstrated acceptable robustness and precision through bootstrap analysis.
- Therapeutic drug monitoring concentrations can be effectively used for pharmacokinetic modeling.
Takeaway
This study shows that how your kidneys work can change how gabapentin works in your body, but being overweight or having diabetes doesn't seem to matter.
Methodology
Data were collected retrospectively from 82 hospitalized adult patients with therapeutic drug monitoring gabapentin concentrations.
Potential Biases
Residual confounding factors may be present due to the observational study design.
Limitations
The study's retrospective nature may introduce inconsistencies, and the sample size is relatively small.
Participant Demographics
The study population was predominantly white, with an average age of 65.7 years and an average BMI of 30.
Statistical Information
P-Value
p ≤ 0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website